Agreement for the Examination of Cooperation with Wize Pharma; Immaterial Relations with an independent Director

Tel Aviv (June 12, 2018) – On June 11, 2018, Diagnostear Ltd. (“Diagnostear“)[1] entered into an agreement (the “Agreement”) with Wize Pharma Ltd. (“Wize Pharma” and together with Diagnostear  the “Parties“) to examine cooperation between the Parties for the development of a companion diagnostic tool of responders and …

Continue reading

Rights Offering Results

Tel Aviv (May 10, 2018) – BioLight Life Sciences Ltd. is pleased to announce the
completion and results of its Rights Offering. The Rights Offering record date was April 26,
2018, and the offer has ended and expired on May 9, 2018.
The Rights Offering entitled rights …

Continue reading

Closing of the first stage of the binding agreement of investment in and acquisition in stages of IOPtima

Tel Aviv (March 29, 2018) – Further to BioLight’s announcement dated November 21, 2017, regarding signing a binding agreement for the investment in and the acquisition in stages of its subsidiary IOPtima Ltd. (the “Agreement”) by the Chinese pharmaceutical company Chengdu Kanghong Pharmaceutical Group Co. (the “Acquirer”), the first stage …

Continue reading

Update regarding Closing of the first stage of the Binding agreement of investment in and acquisition of IOPtima

Tel Aviv (February 11, 2018) – Further to BioLight’s announcement dated November 31, 2017 regarding signing a binding agreement for the investment in and the acquisition in stages of its subsidiary IOPtima (the “Agreement”) by the Chinese pharmaceutical company Chengdu Kanghong Pharmaceutical Group Co. (“the Acquirer”), and in accordance with …

Continue reading

DiagnosTear Ltd. – Recruitment of the first participant for clinical trial using the TeaRx ™ technology

The Company hereby announces that on August 31, 2017, DiagnosTear Ltd. (“DiagnosTear”) announced the recruitment of a first participant for an additional clinical trial to examine a product based on the TeaRx ™ technology, which is used to diagnose, personalize treatment and monitoring Dry eye syndrome by examining the composition …

Continue reading